Using VISTA Pathway to Prevent Graft Versus Host Disease
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
This study is looking at a special antibody that might help prevent aGVHD in patients getting a stem cell transplant by helping the immune system be more accepting, and it aims to see how this treatment affects certain immune cells that are important for keeping aGVHD at bay.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10793490 on NIH RePORTER |
What this research studies
This research investigates the use of a specific monoclonal antibody targeting the VISTA pathway to prevent acute graft versus host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation. The approach involves administering this antibody on the day of the transplant to promote tolerance in the immune system, potentially leading to better outcomes for patients. The study will explore how this treatment affects T cell behavior and the generation of regulatory T cells, which are crucial for preventing aGVHD. By tracking specific T cells in treated models, researchers aim to understand the mechanisms behind this treatment's effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients scheduled to undergo allogeneic hematopoietic cell transplantation who are at risk for developing acute graft versus host disease.
Not a fit: Patients who are not undergoing allogeneic hematopoietic cell transplantation or those with existing severe aGVHD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of acute graft versus host disease in transplant patients, improving their overall survival and quality of life.
How similar studies have performed: Previous research has shown promise in using monoclonal antibodies for immune modulation, but this specific approach targeting the VISTA pathway is relatively novel.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Blazar, Bruce R — University of Minnesota
- Study coordinator: Blazar, Bruce R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.